FDA/NIH Collaboration On Regulatory Science Includes Interest In Cancer, Pain Drugs and Vaccines
This article was originally published in The Pink Sheet Daily
Executive Summary
Grant program is small and open-ended at the outset, but officials offer a long list of needs. A public meeting to gather input on research priorities is set for April.
You may also be interested in...
FDA Regulatory Science Infrastructure Gets $25 Million Push In Budget
Gaining the expertise and infrastructure needed to assess products of the future - such as biosimilars and those based on stem cells and nanotechnology - is the goal of a $25 million scientific modernization effort proposed in the fiscal 2011 FDA budget
Drugs With Abuse Potential Should Recruit Two Types Of Patients For Trials
FDA is encouraging sponsors conducting clinical trials to assess the abuse potential of a new drug to enroll "drug-naive healthy subjects" as well as "experienced, recreational drug users who have a recent or current history of using a drug in the pharmaceutical class of the test drug.
Opioid Risk Management: FDA Not Impressed With Industry Working Group's Proposals
After a meeting that produced little aside from a suggestion that DEA may be able to track physician training, has industry lost its chance to craft a REMS for the pain products?